Progress on diagnostic and prognostic markers of pancreatic cancer
Yang Hong, Wan Li, Liwen Ren, Yihui Yang, Yizhi Zhang, Binbin Ge, Sha Li, Xiangjin Zheng, Jinyi Liu, Sen Zhang, Guanhua DU, BO TANG, Hongquan Wang, Jinhua Wang
Abstract
Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate, whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed. Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens. So far, CA19-9 is the only biomarker for pancreatic cancer approved by the FDA, but its effectiveness is limited by low sensitivity and specificity. With recent advances in genomics, proteomics, metabolomics, and other analytical and sequencing technologies, the rapid acquisition and screening of biomarkers is now possible. Liquid biopsy also occupies a significant place due to its unique advantages. In this review, we systematically describe and evaluate the available biomarkers that have the greatest potential as vital tools in diagnosing and treating pancreatic cancer.